ReviewACS biomaterials science & engineering2020
The Structural Basis of Amyloid Strains in Alzheimer's Disease.
Review in ACS biomaterials science & engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 20 citations in OpenAlex.
- Article
- Review
- Divergent Age-Dependent Conformational Rearrangement within Aβ Amyloid Deposits in APP23, APPPS1, andACS chemical neuroscience · 2024Article
- Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer's disease.Translational neurodegeneration · 2023Article
- Misfolded amyloid-β strains and their potential roles in the clinical and pathological variability of Alzheimer's disease.Neural regeneration research · 2023Article
- The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease.Acta neuropathologica · 2021Review
- Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications.International journal of molecular sciences · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Amyloid fibrils represent one of the defining features of Alzheimer's disease (AD). They are made up of protofilaments composed of amyloid β (Aβ) peptides that are held together with extraordinary stability by a network of tight steric zippers and axial hydrogen bonds. This review explores the hypothesis that the peptide conformation within a protofilament represents the physical embodiment of a "strain" of AD. Evidence suggests that within a single strain the fold of individual peptides is invariant. However, the fibrils are capable of structural polymorphism that includes variation in the arrangement of protofilaments into fibrils, the pitch of the resultant fibrils, and the higher-order organization of the plaques into which they aggregate. These intrastrain polymorphisms are separated by low energy barriers, allowing multiple configurations to coexist within a single preparation or tissue. Clinical presentation of different strains may be determined by variation in the way different protofilament structures generate the relevant toxic species, be they monomers, oligomers, or higher-order structures. Evidence reviewed here is consistent with a model in which disease progression is concomitant with a gradual, progressive annealing of amyloid fibrils from benign, loosely packed structures into dense neurotoxic aggregates. This model challenges the commonly held hypothesis that oligomers of Aβ peptides are the only active proximate species in neurodegeneration. However, the data do not implicate fibrils themselves. Rather, they cast suspicion on larger-scale supramolecular aggregates as toxic agents. Electron tomography of amyloid plaques in situ strongly suggests that the formation of amyloid aggregates results in perturbation of the cellular membrane integrity, warranting further investigation of this as a potential mode of neurotoxicity. If dense supramolecular amyloid aggregates prove to be important agents of neurodegeneration in AD, this model may also have relevance to other forms of amyloidoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.